# Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy

> **NCT02448290** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 25 (actual)

## Conditions studied

- Gastric Adenocarcinoma

## Interventions

- **DRUG:** docetaxel plus selumetinib

## Key facts

- **NCT ID:** NCT02448290
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-12
- **Primary completion:** 2018-05-17
- **Final completion:** 2018-05-17
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02448290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02448290, "Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02448290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*